Liquid Biopsy in Lung Cancer
- Conditions
- Circulating Tumor CellLung Cancer (Diagnosis)
- Registration Number
- NCT03479099
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.
- Detailed Description
The peripheral blood and tumor tissue samples are collected from the participants.CTC and ctDNA are analyzed from the blood samples.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 111
- Patients with histology-proven lung cancer or a clinical suspicion of lung cancer
- Age >=18, < 80 years
- No previous history of cancer treatment within 5 years
- Patients who agree to participate
- Patients who have been diagnosed with malignancy within 5 years
- Patients with previous history of lung cancer
- Patients who have uncontrolled coagulopathy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnostic sensitivity of combined CTC and ctDNA 1 year To compared the sensitivity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
- Secondary Outcome Measures
Name Time Method Diagnostic accuracy of combined CTC and ctDNA 1 year To compared the accuracy of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Diagnostic specificity of CTC and ctDNA 1 year To compared the specificity of combined CTC and ctDNA with those of CTC and ctDNA alone in diagnosis of primary lung cancer
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center🇰🇷Seoul, Korea, Republic of